# Clinical Trial Site Management Plan Template

**Document Control**

| Document Information | Details |
|----------------------|---------|
| Document Title | Clinical Trial Site Management Plan |
| Protocol Number | [PROTOCOL-XXX] |
| Study Title | [FULL STUDY TITLE] |
| Sponsor | [SPONSOR NAME] |
| Version | 1.0 |
| Date | [DATE] |
| Prepared By | [NAME], [TITLE] |
| Approved By | [NAME], [TITLE] |

**Document History**

| Version | Date | Description of Changes | Author |
|---------|------|------------------------|--------|
| 1.0 | [DATE] | Initial version | [NAME] |

---

## Table of Contents

1. [Executive Summary](#1-executive-summary)
2. [Site Selection Process](#2-site-selection-process)
   - 2.1 [Site Feasibility Assessment](#21-site-feasibility-assessment)
   - 2.2 [Selection Criteria](#22-selection-criteria)
   - 2.3 [Documentation Requirements](#23-documentation-requirements)
3. [Site Initiation](#3-site-initiation)
   - 3.1 [Pre-initiation Requirements](#31-pre-initiation-requirements)
   - 3.2 [Site Training Program](#32-site-training-program)
   - 3.3 [Essential Document Collection](#33-essential-document-collection)
4. [Site Monitoring](#4-site-monitoring)
   - 4.1 [Monitoring Strategy](#41-monitoring-strategy)
   - 4.2 [Visit Frequency and Types](#42-visit-frequency-and-types)
   - 4.3 [Source Data Verification](#43-source-data-verification)
   - 4.4 [Quality Control Procedures](#44-quality-control-procedures)
5. [Communication Plan](#5-communication-plan)
   - 5.1 [Reporting Structure](#51-reporting-structure)
   - 5.2 [Escalation Procedures](#52-escalation-procedures)
   - 5.3 [Regular Updates and Meetings](#53-regular-updates-and-meetings)
6. [Risk Management](#6-risk-management)
   - 6.1 [Site-specific Risk Assessment](#61-site-specific-risk-assessment)
   - 6.2 [Risk Mitigation Strategies](#62-risk-mitigation-strategies)
   - 6.3 [Performance Metrics](#63-performance-metrics)
7. [Site Management Tools](#7-site-management-tools)
   - 7.1 [Visit Reports Templates](#71-visit-reports-templates)
   - 7.2 [Issue Tracking Log](#72-issue-tracking-log)
   - 7.3 [Action Item Tracker](#73-action-item-tracker)
8. [Site Closeout Procedures](#8-site-closeout-procedures)
   - 8.1 [Closeout Visit Requirements](#81-closeout-visit-requirements)
   - 8.2 [Document Archival](#82-document-archival)
   - 8.3 [Final Report Requirements](#83-final-report-requirements)
9. [Appendices](#9-appendices)
   - 9.1 [Site Assessment Checklist](#91-site-assessment-checklist)
   - 9.2 [Monitoring Visit Report Template](#92-monitoring-visit-report-template)
   - 9.3 [Site Performance Metrics Dashboard](#93-site-performance-metrics-dashboard)

---

## 1. Executive Summary

This Site Management Plan outlines the procedures and standards for selecting, initiating, monitoring, and closing clinical trial sites for [PROTOCOL-XXX]. The plan ensures consistent, high-quality site performance in compliance with ICH GCP E6(R2), applicable regulatory requirements, and the study protocol.

The plan addresses:
- Standardized processes for site selection, initiation, monitoring, and closeout
- Clear communication channels and escalation procedures
- Risk-based monitoring approach tailored to this study's specific needs
- Tools and templates to ensure consistent documentation and tracking
- Performance metrics to evaluate site progress and quality

This document serves as a guide for the clinical operations team, clinical research associates (CRAs), and other personnel involved in site management activities. It should be used in conjunction with the Clinical Trial Protocol and other study-specific documents.

---

## 2. Site Selection Process

### 2.1 Site Feasibility Assessment

The site feasibility assessment will evaluate potential sites based on their capability to conduct the clinical trial according to the protocol requirements and GCP standards.

**Feasibility Assessment Process:**

1. **Initial screening**: Review of site's experience, capabilities, and interest through questionnaires
2. **Pre-selection site visit**: On-site evaluation of facilities, staff, and resources
3. **Historical performance analysis**: Review of site's performance in previous trials
4. **Patient population assessment**: Evaluation of potential subject pool and recruitment capabilities

**Key Feasibility Parameters:**

| Parameter | Assessment Method | Acceptance Criteria |
|-----------|-------------------|---------------------|
| Patient Population | Feasibility questionnaire, EMR data review | Access to [X] eligible patients within [Y] months |
| Investigator Experience | CV review, publication history | Minimum [X] years in clinical trials, [Y] trials in relevant therapeutic area |
| Staff Qualifications | Staff credentials review | Certified research coordinators with GCP training |
| Facilities | Site visit inspection | Appropriate space for trial procedures, secure storage for IP, calibrated equipment |
| Competing Studies | Interview with site staff | No competing studies that would impact recruitment |
| Regulatory History | Review of FDA 483s, warning letters | No significant findings in past 3 years |

### 2.2 Selection Criteria

Sites will be selected based on the following criteria:

**Essential Criteria (All must be met):**
- Qualified principal investigator with experience in [THERAPEUTIC AREA]
- Adequate patient population that meets inclusion/exclusion criteria
- Adequate facilities and equipment to perform protocol-required procedures
- Demonstrated GCP compliance
- Capacity to allocate sufficient resources to the study
- Acceptable institutional review board (IRB)/ethics committee (EC) timelines

**Desirable Criteria (Prioritized):**
- Previous successful collaboration with sponsor/CRO
- Strong track record of enrollment performance
- Low historical protocol deviation rates
- Experienced study coordinator and research staff
- Established quality management systems
- Geographic location facilitating monitoring visits

**Selection Scoring System:**

| Category | Weight | Score (1-5) | Weighted Score |
|----------|--------|-------------|----------------|
| Investigator qualifications | 20% | | |
| Patient access | 25% | | |
| Site resources | 15% | | |
| Previous performance | 20% | | |
| Quality metrics | 10% | | |
| Startup timelines | 10% | | |
| **TOTAL** | 100% | | |

A minimum score of [X] is required for site selection.

### 2.3 Documentation Requirements

The following documentation must be collected and reviewed during the site selection process:

**Required Documents:**
- Completed feasibility questionnaire
- Investigator CV and medical license
- Site staff CVs and training certificates
- Publication history in relevant therapeutic area
- Site visit reports
- Previous audit findings (if applicable)
- Historical enrollment metrics
- Conflict of interest disclosures
- Equipment calibration records
- Standard operating procedures relevant to the trial

All documentation will be stored in the Trial Master File (TMF) in accordance with ICH GCP requirements and sponsor SOPs.

---

## 3. Site Initiation

### 3.1 Pre-initiation Requirements

Before site initiation, the following requirements must be met:

**Regulatory Requirements:**
- IRB/EC approval obtained
- Regulatory authority approval (if applicable)
- Executed Clinical Trial Agreement
- Executed Confidentiality Agreement
- Finalized site budget
- Investigator's Brochure acknowledgment
- Financial disclosure forms completed

**Facility and Staff Requirements:**
- Adequate space allocation confirmed
- Required equipment available and calibrated
- Staff roles and responsibilities defined
- Delegation of authority log completed
- 24-hour emergency contact information established
- IP storage conditions verified

**Pre-initiation Checklist:**

| Requirement | Status | Comments | Responsible Person |
|-------------|--------|----------|---------------------|
| IRB/EC approval | | | |
| Regulatory submissions | | | |
| Contract execution | | | |
| Budget finalization | | | |
| Essential documents collection | | | |
| Facility readiness | | | |
| Staff availability | | | |

### 3.2 Site Training Program

A comprehensive training program will be implemented at each site to ensure all staff are qualified to conduct the trial according to the protocol.

**Training Program Components:**

1. **Protocol Training:**
   - Study design and objectives
   - Inclusion/exclusion criteria
   - Study procedures and schedule of assessments
   - Protocol deviations and violations reporting

2. **GCP and Regulatory Training:**
   - ICH GCP E6(R2) principles
   - Regulatory requirements
   - Informed consent process
   - Safety reporting requirements

3. **Study-Specific Procedures Training:**
   - Clinical assessments
   - Sample collection, processing, and shipping
   - Electronic data capture (EDC) system
   - Interactive response technology (IRT) system
   - Laboratory procedures

4. **IP Management Training:**
   - Receipt, storage, and handling
   - Accountability and reconciliation
   - Temperature monitoring and excursion reporting
   - Return and destruction procedures

**Training Documentation:**

All training will be documented using a standardized training log that includes:
- Training topic
- Date of training
- Training materials used
- Trainer name and qualifications
- Attendee names and signatures
- Assessment of comprehension (if applicable)

Refresher training will be conducted as needed throughout the study.

### 3.3 Essential Document Collection

The following essential documents must be collected before or during site initiation:

**Regulatory Documents:**
- IRB/EC approval letter and approved ICF
- IRB/EC roster and Federal Wide Assurance (FWA) number
- Regulatory authority approval (if applicable)
- Form FDA 1572 (for US sites)
- Financial disclosure forms
- Signed protocol and amendments
- CV and medical license for all investigators
- Laboratory certifications and normal ranges

**Study-Specific Documents:**
- Delegation of authority log
- Training documentation
- Screening and enrollment log
- Subject identification code list
- IP accountability logs
- Monitoring log
- Site signature log
- Protocol deviation log

**Essential Document Tracker:**

| Document | Required | Received | Filing Location | Comments |
|----------|----------|----------|-----------------|----------|
| IRB/EC approval letter | Yes | | | |
| Signed protocol | Yes | | | |
| Investigator CV | Yes | | | |
| Medical license | Yes | | | |
| Financial disclosure | Yes | | | |
| Form FDA 1572 | US only | | | |
| Lab certification | Yes | | | |
| Normal lab ranges | Yes | | | |

All essential documents will be maintained in accordance with ICH GCP Section 8 and filed appropriately in the Investigator Site File (ISF) and Trial Master File (TMF).

---

## 4. Site Monitoring

### 4.1 Monitoring Strategy

This study will utilize a risk-based monitoring (RBM) approach in accordance with ICH GCP E6(R2), focusing resources on critical data and processes while maintaining compliance and data integrity.

**Risk-Based Monitoring Framework:**

1. **Risk Assessment:**
   - Identification of critical data and processes
   - Determination of risk indicators
   - Establishment of risk thresholds
   - Documentation in the Risk Assessment and Categorization Tool (RACT)

2. **Monitoring Plan Development:**
   - Tailored to site risk level
   - Combination of on-site and remote monitoring
   - Centralized data monitoring strategy
   - Adaptive approach based on site performance

3. **Key Risk Indicators (KRIs):**
   - Enrollment rate deviations
   - Protocol deviation frequency
   - Data entry timeliness
   - Query resolution time
   - Missing data rate
   - Adverse event reporting compliance
   - Consent process compliance
   - IP accountability issues

**Monitoring Approach by Site Risk Level:**

| Risk Level | On-site Frequency | Remote Monitoring | Centralized Monitoring | SDV Approach |
|------------|-------------------|-------------------|------------------------|--------------|
| High | Every 4-6 weeks | Biweekly | Weekly data review | 100% for critical data, 50% for non-critical |
| Medium | Every 8-10 weeks | Monthly | Biweekly data review | 50% for critical data, 25% for non-critical |
| Low | Every 12-16 weeks | Monthly | Monthly data review | 25% for critical data, 10% for non-critical |

### 4.2 Visit Frequency and Types

**Visit Types and Objectives:**

1. **Site Initiation Visit (SIV):**
   - Confirm site readiness
   - Deliver protocol and procedure training
   - Verify essential documents
   - Review regulatory requirements
   - Establish communication channels

2. **Interim Monitoring Visits (IMV):**
   - Verify protocol compliance
   - Perform source data verification
   - Review essential documents
   - Assess regulatory compliance
   - Check IP accountability
   - Verify adverse event reporting
   - Address site questions and issues

3. **For-Cause Visits:**
   - Investigate significant protocol deviations
   - Address data quality concerns
   - Respond to safety issues
   - Provide remedial training
   - Implement corrective actions

4. **Close-Out Visit (COV):**
   - Verify complete and accurate data
   - Reconcile IP
   - Review essential document completeness
   - Discuss record retention requirements
   - Address outstanding issues

**Visit Schedule:**

| Visit Type | Timing | Duration | Key Personnel Required |
|------------|--------|----------|------------------------|
| SIV | After all pre-initiation requirements met | 1 day | PI, SC, Study Staff |
| First IMV | Within 4 weeks of first subject enrolled | 1 day | SC, Study Staff |
| Routine IMVs | Per risk-based schedule | 1 day | SC, Study Staff |
| COV | After last subject last visit | 1 day | PI, SC, Study Staff |

### 4.3 Source Data Verification

Source Data Verification (SDV) will be conducted according to a risk-based approach, focusing on critical data points while ensuring overall data quality and integrity.

**Critical Data Elements for 100% SDV:**
- Informed consent documentation
- Eligibility criteria
- Primary efficacy endpoints
- Key secondary efficacy endpoints
- Serious adverse events (SAEs)
- Study drug administration
- Protocol-defined safety parameters
- Withdrawal/discontinuation information

**Non-Critical Data Elements for Risk-Based SDV:**
- Demographics
- Medical history
- Physical examinations
- Concomitant medications
- Non-critical laboratory values
- Quality of life assessments

**SDV Documentation:**

The CRA will document all SDV activities, including:
- Data points verified
- Source documents reviewed
- Discrepancies identified
- Corrections requested
- Resolution of previous findings

**Source Data Review (SDR):**

In addition to SDV, Source Data Review will be conducted to assess:
- Data consistency across source documents
- Protocol compliance
- Data trends suggestive of systemic issues
- Potential unreported adverse events
- Informed consent process compliance

### 4.4 Quality Control Procedures

Quality control procedures will be implemented to ensure data integrity, protocol compliance, and GCP adherence throughout the study.

**Quality Control Measures:**

1. **Data Quality Checks:**
   - Real-time edit checks in EDC system
   - Centralized statistical monitoring
   - Cross-verification of critical data points
   - Logical consistency checks

2. **Protocol Compliance Verification:**
   - Review of schedule of assessments adherence
   - Verification of procedure technique compliance
   - Confirmation of visit windows adherence
   - Documentation of protocol deviations

3. **Document Control:**
   - Version control for all study documents
   - Regular ISF review and organization
   - Proper correction procedures (single line, dated, initialed)
   - Chain of custody documentation

4. **Site Staff Oversight:**
   - Verification of delegation log currency
   - Confirmation of appropriate task delegation
   - Validation of staff qualifications
   - Assessment of training effectiveness

**Quality Metrics Tracking:**

| Quality Metric | Target | Monitoring Method | Action Threshold |
|----------------|--------|-------------------|------------------|
| Protocol deviation rate | <5% per site | Site monitoring | >10% triggers increased monitoring |
| Data entry timeliness | Within 5 days of collection | EDC metrics | >10 days triggers notification |
| Query resolution time | Within 7 days | EDC metrics | >14 days triggers escalation |
| Missing data rate | <2% of required fields | EDC metrics | >5% triggers data review |
| Consent form completion | 100% compliance | Source review | Any deficiency triggers immediate action |

---

## 5. Communication Plan

### 5.1 Reporting Structure

A clear reporting structure will be established to ensure efficient communication and oversight throughout the study.

**Communication Hierarchy:**

```
Study Sponsor
    │
    ▼
Project Manager/Clinical Trial Manager
    │
    ├─────────────┬─────────────┬─────────────┐
    ▼             ▼             ▼             ▼
Clinical Lead   Medical        Data          Safety
                Monitor        Manager       Manager
    │
    ▼
Clinical Research Associates (CRAs)
    │
    ▼
Site Staff (PI, Sub-Investigators, Study Coordinators)
```

**Key Contact Information:**

| Role | Name | Contact Information | Response Time Expectation |
|------|------|---------------------|---------------------------|
| Project Manager | [NAME] | Email: [EMAIL]<br>Phone: [PHONE] | 24 hours |
| Medical Monitor | [NAME] | Email: [EMAIL]<br>Phone: [PHONE] | 24 hours (SAEs: immediate) |
| Lead CRA | [NAME] | Email: [EMAIL]<br>Phone: [PHONE] | 48 hours |
| Site CRA | [NAME] | Email: [EMAIL]<br>Phone: [PHONE] | 48 hours |
| Safety Manager | [NAME] | Email: [EMAIL]<br>Phone: [PHONE] | 24 hours |
| Data Manager | [NAME] | Email: [EMAIL]<br>Phone: [PHONE] | 48 hours |

### 5.2 Escalation Procedures

A standardized escalation process will be implemented to address issues requiring prompt attention or resolution.

**Escalation Pathway:**

1. **Level 1 (Site CRA):**
   - Minor protocol deviations
   - Routine queries and clarifications
   - Documentation deficiencies
   - Minor enrollment delays

2. **Level 2 (Lead CRA/Clinical Lead):**
   - Significant protocol deviations
   - Persistent documentation issues
   - Moderate enrollment delays
   - Site staff changes
   - Recurring issues previously addressed

3. **Level 3 (Project Manager):**
   - Major protocol violations
   - Significant GCP non-compliance
   - Substantial enrollment shortfalls
   - Site relationship challenges
   - Issues requiring sponsor input

4. **Level 4 (Sponsor Management):**
   - Critical safety concerns
   - Potential regulatory impact
   - Investigator performance issues
   - Site suspension considerations
   - Issues affecting study integrity

**Escalation Timeline Requirements:**

| Issue Severity | Notification Timeline | Documentation | Follow-up Requirement |
|----------------|------------------------|---------------|------------------------|
| Mild | Within 5 business days | Email/Monitoring report | Next scheduled visit |
| Moderate | Within 3 business days | Formal memo | Within 2 weeks |
| Significant | Within 24 hours | Incident report | Within 1 week |
| Critical | Immediate | Incident report + call | Within 24-48 hours |

### 5.3 Regular Updates and Meetings

A schedule of regular meetings and communications will be established to ensure consistent information flow and study oversight.

**Meeting Schedule:**

| Meeting Type | Frequency | Participants | Purpose | Documentation |
|--------------|-----------|--------------|---------|---------------|
| Investigator Meeting | Study start and annually | All investigators, key site staff, sponsor team | Protocol training, study updates, best practice sharing | Meeting minutes, attendance log |
| CRA Team Meeting | Biweekly | CRAs, Clinical Lead, Project Manager | Site performance review, issue discussion, best practice sharing | Meeting minutes, action items |
| Site Management Call | Monthly | CRA, PI, SC | Enrollment status, upcoming activities, issue resolution | Call notes, action items |
| Project Team Meeting | Monthly | PM, Clinical Lead, Data Manager, Safety Manager, Medical Monitor | Overall study progress, timeline review, risk assessment | Meeting minutes, action items |
| Site Newsletter | Quarterly | All sites | Study updates, enrollment status, reminders, best practices | Newsletter archive |

**Communication Methods:**

- **Email:** Primary method for routine communications and documentation
- **Telephone:** Immediate issues requiring discussion
- **Video Conference:** Team meetings and site discussions requiring visual elements
- **Study Portal/Website:** Repository for study documents and announcements
- **EDC System:** Data clarifications and query management

---

## 6. Risk Management

### 6.1 Site-specific Risk Assessment

A site-specific risk assessment will be conducted for each participating site to identify, evaluate, and mitigate potential risks.

**Risk Assessment Process:**

1. **Initial Assessment:**
   - Conducted during site selection and SIV
   - Based on site feasibility, qualification visit, and historical performance
   - Documented in the Site Risk Assessment Tool

2. **Ongoing Assessment:**
   - Updated after each monitoring visit
   - Incorporates performance metrics and observed issues
   - Triggers adjustments to monitoring strategy as needed

3. **Risk Categorization:**
   - Sites classified as Low, Medium, or High risk
   - Classification determines monitoring intensity and focus
   - Re-evaluated quarterly or after significant findings

**Site Risk Assessment Matrix:**

| Risk Category | Risk Factors | Risk Level Assessment |
|---------------|-------------|------------------------|
| Investigator/Staff | Experience level<br>Workload<br>Turnover<br>Training<br>Protocol knowledge | Low/Medium/High |
| Recruitment | Population access<br>Competing studies<br>Historical performance<br>Recruitment strategy | Low/Medium/High |
| Facility | Equipment availability<br>Space adequacy<br>Sample processing capabilities<br>IP storage conditions | Low/Medium/High |
| Data Quality | Error rates<br>Query volume<br>Timeliness<br>Missing data<br>Inconsistencies | Low/Medium/High |
| Protocol Compliance | Deviation history<br>Complexity of procedures<br>Visit schedule adherence<br>Eligibility assessment accuracy | Low/Medium/High |
| Regulatory Compliance | ICF process<br>IRB communication<br>Documentation practices<br>AE reporting timeliness | Low/Medium/High |

### 6.2 Risk Mitigation Strategies

For each identified risk, appropriate mitigation strategies will be implemented and monitored.

**Common Risks and Mitigation Approaches:**

| Risk | Mitigation Strategy | Responsible Party | Monitoring Method |
|------|---------------------|-------------------|-------------------|
| Inadequate subject recruitment | Develop site-specific recruitment plan<br>Provide recruitment materials<br>Regular recruitment check-ins<br>Consider recruitment support | CRA, Project Manager | Weekly enrollment reports |
| Protocol deviations | Enhanced protocol training<br>Procedure quick reference guides<br>Frequent remote check-ins<br>Focused protocol compliance monitoring | CRA, Medical Monitor | Deviation log review |
| Staff turnover | Cross-training of multiple staff members<br>Comprehensive training materials<br>Rapid retraining for new staff<br>Temporary support during transitions | CRA, Clinical Lead | Staff qualification log |
| Data entry delays | EDC system training<br>Regular data entry reminders<br>Data entry performance metrics<br>Assistance with backlog if needed | CRA, Data Manager | EDC metrics reports |
| IP management issues | Enhanced IP training<br>Simplified accountability forms<br>Regular remote IP reconciliation<br>Additional monitoring of IP processes | CRA, Clinical Supply Manager | IP accountability logs |

**Risk Mitigation Documentation:**

All risk mitigation activities will be documented in:
- Site Risk Management Plans
- Monitoring visit reports
- Follow-up letters to sites
- Study team meeting minutes
- Corrective and Preventive Action (CAPA) plans when applicable

### 6.3 Performance Metrics

Key performance indicators (KPIs) will be tracked to evaluate site performance and identify areas requiring intervention.

**Site Performance Metrics:**

| Performance Category | Metrics | Target | Reporting Frequency |
|----------------------|---------|--------|---------------------|
| Enrollment | Subjects screened per month<br>Screen failure rate<br>Enrollment rate vs. target<br>Retention rate | Site-specific targets | Weekly |
| Data Quality | Query rate per CRF<br>Days to query resolution<br>Missing data percentage<br>Data entry timeliness | Query rate <10%<br>Resolution <7 days<br>Missing data <2%<br>Entry within 5 days | Biweekly |
| Protocol Compliance | Major deviation rate<br>Minor deviation rate<br>Visit window compliance<br>Procedure completion rate | Major <1%<br>Minor <5%<br>Window >90%<br>Completion >95% | Monthly |
| Regulatory Compliance | SAE reporting timeliness<br>IRB submission timeliness<br>Essential document completeness | 100% within timelines | Monthly |
| Staff Performance | Training completion<br>Response time to queries<br>Communication responsiveness | 100% trained<br><7 days for queries<br><48 hours response | Quarterly |

**Performance Dashboard:**

A site performance dashboard will be updated monthly and shared with the study team to facilitate performance tracking and intervention planning.

---

## 7. Site Management Tools

### 7.1 Visit Reports Templates

Standardized templates will be used to document all site visits, ensuring consistent and comprehensive documentation.

**Site Visit Report Templates:**

1. **Site Initiation Visit (SIV) Report:**
   - Site readiness assessment
   - Training documentation
   - Essential document verification
   - Outstanding items and action plan
   - Site activation recommendation

2. **Interim Monitoring Visit (IMV) Report:**
   - Enrollment status
   - Protocol compliance review
   - Source data verification summary
   - Essential document review
   - IP accountability
   - Outstanding issues and action items
   - Site performance assessment

3. **For-Cause Visit Report:**
   - Issue investigation findings
   - Root cause analysis
   - Corrective actions implemented
   - Preventive measures established
   - Follow-up requirements

4. **Close-Out Visit (COV) Report:**
   - Final data verification status
   - IP reconciliation results
   - Essential document completeness
   - Record retention instructions
   - Outstanding issues resolution
   - Site closure recommendation

**Report Completion and Review Timeline:**

| Report Type | Completion Deadline | Review Level 1 | Review Level 2 | Finalization |
|-------------|---------------------|----------------|----------------|--------------|
| SIV Report | 5 business days | Lead CRA: 2 days | Clinical Lead: 3 days | Within 10 business days of visit |
| IMV Report | 5 business days | Lead CRA: 2 days | As needed | Within 7 business days of visit |
| For-Cause Report | 3 business days | Lead CRA: 1 day | Clinical Lead: 2 days | Within 6 business days of visit |
| COV Report | 5 business days | Lead CRA: 2 days | Clinical Lead: 3 days | Within 10 business days of visit |

### 7.2 Issue Tracking Log

A centralized issue tracking system will be maintained to document, track, and resolve site issues throughout the study.

**Issue Tracking Elements:**

| Field | Description | Required |
|-------|-------------|----------|
| Issue ID | Unique identifier | Yes |
| Site Number | Affected site | Yes |
| Date Identified | Discovery date | Yes |
| Identified By | Person who discovered issue | Yes |
| Description | Detailed issue description | Yes |
| Category | Protocol, Regulatory, Data, IP, Safety, Other | Yes |
| Severity | Critical, Major, Minor | Yes |
| Impact | Study integrity, data quality, subject safety, timeline | Yes |
| Action Plan | Steps to resolve issue | Yes |
| Responsible Party | Person assigned to resolution | Yes |
| Target Resolution Date | Expected completion date | Yes |
| Status | Open, In Progress, Resolved, Closed | Yes |
| Actual Resolution Date | Date issue was resolved | When resolved |
| Preventive Action | Measures to prevent recurrence | When resolved |
| Related Documents | Links to supporting documentation | As applicable |

**Issue Escalation Criteria:**

| Severity | Definition | Escalation Requirement | Timeline |
|----------|------------|------------------------|----------|
| Critical | Impacts subject safety, data integrity, or regulatory compliance | Project Manager, Medical Monitor, Sponsor | Immediate |
| Major | Significant protocol deviation or recurring issue | Clinical Lead, Project Manager | Within 24 hours |
| Minor | Limited impact, isolated occurrence | Lead CRA | Within 5 business days |

### 7.3 Action Item Tracker

An action item tracker will be maintained for each site to ensure timely completion of required tasks and follow-up activities.

**Action Item Tracker Format:**

| Field | Description | Required |
|-------|-------------|----------|
| Action Item ID | Unique identifier | Yes |
| Site Number | Affected site | Yes |
| Description | Detailed action item description | Yes |
| Source | Visit report, issue log, team meeting, etc. | Yes |
| Priority | High, Medium, Low | Yes |
| Assigned To | Responsible person | Yes |
| Assigned Date | Date task was assigned | Yes |
| Due Date | Deadline for completion | Yes |
| Status | Not Started, In Progress, Completed, Overdue | Yes |
| Completion Date | Date task was completed | When completed |
| Comments | Additional notes or context | As needed |
| Follow-up Required | Yes/No | Yes |
| Follow-up Description | Details of additional steps needed | If follow-up required |

**Action Item Review Schedule:**

- Weekly review of high-priority items
- Biweekly review of all open items
- Monthly comprehensive review with site staff
- Quarterly analysis of trends and systemic issues

---

## 8. Site Closeout Procedures

### 8.1 Closeout Visit Requirements

The site closeout visit will be conducted after the last subject has completed the last visit at the site and all data queries have been resolved.

**Closeout Visit Preparation:**

1. **Pre-Closeout Assessment:**
   - Verification that all subjects have completed the study
   - Confirmation that all data has been entered in EDC
   - Verification that all queries have been resolved
   - Preliminary IP reconciliation
   - IRB/EC notification of study end

2. **Closeout Visit Scheduling:**
   - Coordinated with PI and key site staff
   - Scheduled within [X] days of last subject last visit
   - Adequate time allocated (typically 1 full day)
   - Confirmation of document availability

**Closeout Visit Activities:**

| Activity | Description | Documentation |
|----------|-------------|---------------|
| Final SDV | Verification of any outstanding data points | SDV documentation |
| Query Resolution | Confirmation all queries are resolved | EDC query report |
| IP Reconciliation | Final accountability and return/destruction | IP accountability logs |
| Essential Document Review | Verification of ISF completeness | Document checklist |
| Equipment Return/Disposition | Return of any sponsor-provided equipment | Equipment transfer form |
| Payment Status Review | Verification of payment status | Payment tracking log |
| Record Retention Review | Instructions for record maintenance | Record retention form |
| Publication Policy Review | Discussion of publication process | Meeting notes |
| Future Study Opportunities | Discussion of upcoming trials | Meeting notes |

### 8.2 Document Archival

Proper archiving of study documents will be ensured in accordance with ICH GCP and applicable regulatory requirements.

**Document Retention Requirements:**

- Retention period: Minimum of [X] years after study completion
- Format requirements: Original documents preferred, certified copies acceptable
- Storage conditions: Secure, with limited access, protected from damage
- Retrieval process: Documented system for locating archived materials

**Archival Process:**

1. **Document Inventory:**
   - Complete inventory of all essential documents
   - Verification of document completeness
   - Identification of any missing documents
   - Resolution of documentation gaps

2. **Preparation for Archiving:**
   - Organization of documents according to ICH GCP structure
   - Removal of duplicate materials
   - Proper labeling of all files and boxes
   - Creation of detailed index

3. **Archive Transfer:**
   - Selection of appropriate archive facility
   - Completion of archive transfer forms
   - Secure transport to archive location
   - Confirmation of receipt and storage

**Archival Documentation:**

| Document | Purpose | Required Elements |
|----------|---------|-------------------|
| Document Inventory | Lists all archived materials | Document names, dates, versions, quantity |
| Archive Box Log | Tracks contents of each box | Box number, content summary, date range |
| Archive Transfer Form | Documents transfer to facility | Sender, recipient, transfer date, contents |
| Retention Certificate | Confirms archiving requirements | Retention period, retrieval process, destruction date |
| Access Log | Records document access | Requester, date, purpose, materials accessed |

### 8.3 Final Report Requirements

A comprehensive final report will be prepared for each site to document study completion and site performance.

**Final Report Components:**

1. **Study Summary:**
   - Protocol overview
   - Site participation dates
   - Enrollment summary
   - Key milestones

2. **Site Performance Assessment:**
   - Recruitment performance
   - Protocol compliance
   - Data quality metrics
   - Regulatory compliance
   - Overall performance rating

3. **Issue Summary:**
   - Major issues encountered
   - Resolution of critical findings
   - Systemic challenges
   - Lessons learned

4. **Administrative Closure:**
   - Final payment status
   - Equipment disposition
   - Document archiving confirmation
   - Future collaboration potential

**Final Report Distribution:**

| Recipient | Timeline | Format | Follow-up Requirements |
|-----------|----------|--------|------------------------|
| Principal Investigator | Within 30 days of closeout | Electronic and hard copy | Acknowledgment of receipt |
| Sponsor | Within 30 days of closeout | Electronic | Review and approval |
| CRO Archives | Within 30 days of closeout | Electronic | Filing confirmation |
| IRB/EC | Per IRB requirements | Per IRB requirements | According to IRB policies |

---

## 9. Appendices

### 9.1 Site Assessment Checklist

**Site Feasibility Assessment Checklist**

| Category | Assessment Item | Yes | No | N/A | Comments |
|----------|----------------|-----|-----|-----|----------|
| **Investigator Experience** |
| | Experience in relevant therapeutic area | | | | |
| | Previous clinical trial experience | | | | |
| | GCP training current | | | | |
| | Publication history | | | | |
| | Adequate time commitment available | | | | |
| **Patient Population** |
| | Access to required patient population | | | | |
| | Historical enrollment performance | | | | |
| | Competing study conflicts | | | | |
| | Referral network established | | | | |
| | Realistic enrollment projections | | | | |
| **Facility Assessment** |
| | Adequate clinic space | | | | |
| | Required equipment available | | | | |
| | Laboratory capabilities | | | | |
| | Secure IP storage | | | | |
| | Emergency equipment access | | | | |
| | Private informed consent area | | | | |
| **Staff Resources** |
| | Adequate study coordinator time | | | | |
| | Qualified support staff | | | | |
| | Staff GCP training | | | | |
| | After-hours coverage plan | | | | |
| | Delegation planning appropriate | | | | |
| **Regulatory History** |
| | Previous audit findings | | | | |
| | FDA inspection history | | | | |
| | IRB/EC relationship | | | | |
| | IRB/EC review timelines | | | | |
| | Previous protocol compliance | | | | |

**Overall Assessment:**
- [ ] Highly Recommended
- [ ] Recommended
- [ ] Recommended with Conditions (specify):
- [ ] Not Recommended

**Assessor Name:** _______________________
**Date:** _______________________
**Signature:** _______________________

### 9.2 Monitoring Visit Report Template

**Interim Monitoring Visit Report**

**Site Number:** [SITE NUMBER]  
**Principal Investigator:** [PI NAME]  
**Visit Date:** [DATE]  
**CRA Name:** [CRA NAME]  

**Visit Information:**
- Visit Number: [X] of [Y]
- Previous Visit Date: [DATE]
- Next Planned Visit: [DATE]

**Site Staff Present:**
- [NAME], [ROLE]
- [NAME], [ROLE]
- [NAME], [ROLE]

**1. Enrollment Status:**

| Category | Target | Actual | % of Target | Comments |
|----------|--------|--------|-------------|----------|
| Screened | | | | |
| Screen Failures | | | | |
| Enrolled | | | | |
| Active | | | | |
| Completed | | | | |
| Discontinued | | | | |

**2. Source Document Review:**

| Category | # Reviewed | # with Findings | Major Findings Summary |
|----------|------------|-----------------|------------------------|
| Informed Consent | | | |
| Eligibility Criteria | | | |
| Primary Endpoints | | | |
| Safety Assessments | | | |
| Concomitant Medications | | | |
| Protocol Procedures | | | |

**3. Protocol Deviations:**

| Deviation Type | # Identified | # Previously Reported | # New | Resolution Status |
|----------------|--------------|------------------------|-------|-------------------|
| Inclusion/Exclusion | | | | |
| Study Procedures | | | | |
| IP Administration | | | | |
| Visit Windows | | | | |
| SAE Reporting | | | | |
| Other | | | | |

**4. Investigational Product Accountability:**

| IP Name | Quantity Received | Quantity Dispensed | Quantity Returned | Reconciled (Y/N) |
|---------|-------------------|--------------------|--------------------|------------------|
| | | | | |
| | | | | |

Storage conditions checked: [ ] Yes [ ] No  
Temperature logs reviewed: [ ] Yes [ ] No  
Findings: _______________________

**5. Essential Documents Review:**

| Document Category | Reviewed | Complete | Findings |
|-------------------|----------|----------|----------|
| Regulatory Approvals | [ ] | [ ] | |
| CVs and Licenses | [ ] | [ ] | |
| Training Documentation | [ ] | [ ] | |
| Delegation Log | [ ] | [ ] | |
| Subject Logs | [ ] | [ ] | |
| SAE Documentation | [ ] | [ ] | |

**6. Action Items from Previous Visit:**

| Action Item | Responsible Person | Due Date | Status | Comments |
|-------------|---------------------|----------|--------|----------|
| | | | | |
| | | | | |

**7. New Action Items:**

| Action Item | Responsible Person | Due Date | Priority |
|-------------|---------------------|----------|----------|
| | | | |
| | | | |

**8. Overall Site Assessment:**

| Category | Rating (Excellent/Good/Fair/Poor) | Comments |
|----------|-----------------------------------|----------|
| Protocol Compliance | | |
| Data Quality | | |
| Subject Safety | | |
| IP Management | | |
| Regulatory Compliance | | |
| Communication | | |
| Overall Performance | | |

**9. CRA Comments and Recommendations:**
_______________________
_______________________
_______________________

**Report Prepared By:** _______________________  
**Date:** _______________________

**Reviewed By:** _______________________  
**Date:** _______________________

### 9.3 Site Performance Metrics Dashboard

**Site Performance Metrics Dashboard**

**Site Number:** [SITE NUMBER]  
**Principal Investigator:** [PI NAME]  
**Reporting Period:** [START DATE] to [END DATE]  

**1. Enrollment Metrics:**

```
Enrollment Progress Chart
[Graphical representation of enrollment over time with target line]
```

| Metric | Target | Current | Status | Trend |
|--------|--------|---------|--------|-------|
| Subjects Screened | | | | ↑/↓/→ |
| Screen Failure Rate | <30% | | | ↑/↓/→ |
| Randomized/Enrolled | | | | ↑/↓/→ |
| Enrollment Rate (subjects/month) | | | | ↑/↓/→ |
| Retention Rate | >90% | | | ↑/↓/→ |
| Early Termination Rate | <10% | | | ↑/↓/→ |

**2. Quality Metrics:**

```
Query Rate Trend
[Line graph showing query rate over time]
```

| Metric | Target | Current | Status | Trend |
|--------|--------|---------|--------|-------|
| Open Queries | <10 | | | ↑/↓/→ |
| Average Days to Query Resolution | <7 days | | | ↑/↓/→ |
| Query Rate per Subject | <5 | | | ↑/↓/→ |
| Data Entry Timeliness | <5 days | | | ↑/↓/→ |
| Missing Data Rate | <2% | | | ↑/↓/→ |
| SDV Discrepancy Rate | <5% | | | ↑/↓/→ |

**3. Protocol Compliance:**

```
Protocol Deviation Trend
[Bar graph showing deviations by category]
```

| Metric | Target | Current | Status | Trend |
|--------|--------|---------|--------|-------|
| Major Protocol Deviations | 0 | | | ↑/↓/→ |
| Minor Protocol Deviations | <3 per subject | | | ↑/↓/→ |
| Visit Window Compliance | >90% | | | ↑/↓/→ |
| Procedure Completion Rate | >95% | | | ↑/↓/→ |
| ICF Documentation Compliance | 100% | | | ↑/↓/→ |

**4. Regulatory Compliance:**

| Metric | Target | Current | Status | Trend |
|--------|--------|---------|--------|-------|
| SAE Reporting Timeliness | 100% within 24h | | | ↑/↓/→ |
| IRB Submission Timeliness | 100% on time | | | ↑/↓/→ |
| Essential Document Completeness | 100% | | | ↑/↓/→ |
| Training Documentation | 100% | | | ↑/↓/→ |

**5. Investigational Product Management:**

| Metric | Target | Current | Status | Trend |
|--------|--------|---------|--------|-------|
| IP Accountability Accuracy | 100% | | | ↑/↓/→ |
| Temperature Excursions | 0 | | | ↑/↓/→ |
| IP Dispensing Errors | 0 | | | ↑/↓/→ |
| Return/Destruction Compliance | 100% | | | ↑/↓/→ |

**6. Monitoring Metrics:**

| Metric | Target | Current | Status | Trend |
|--------|--------|---------|--------|-------|
| Days Since Last Monitoring Visit | <60 days | | | ↑/↓/→ |
| Action Item Completion Rate | >90% | | | ↑/↓/→ |
| Average Days to Close Action Items | <14 days | | | ↑/↓/→ |
| Monitoring Finding Resolution Rate | >95% | | | ↑/↓/→ |

**7. Overall Site Performance Rating:**

```
Performance Radar Chart
[Radar chart showing performance across key dimensions]
```

| Performance Category | Score (1-5) | Previous Score | Change |
|----------------------|-------------|----------------|--------|
| Enrollment Performance | | | |
| Data Quality | | | |
| Protocol Compliance | | | |
| Regulatory Compliance | | | |
| IP Management | | | |
| Site Responsiveness | | | |
| **Overall Rating** | | | |

**Performance Improvement Plan Required:** [ ] Yes [ ] No

**Comments:**
_______________________
_______________________

**Generated By:** _______________________  
**Date:** _______________________
